Myeloid-Associated Antigen Expression in Childhood Acute Lymphoblastic Leukemia

Fink, Franz‐Martin; Köller, Ursula; Mayer, H.; Haas, Oskar A.; Grümayer, E. R.; Urban, Christian; Dengg, Kathrin; Mutz, I; Tüchler, Heinz; Gatterer-Menz, Irmgard; Knapp, Walter; Gadner, Helmut

doi:10.1007/978-3-642-84895-7_7

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chromosomal abnormalities were noted in 40% of co-expressing acute leukemias, and this was not different from the historical control group. There have been several reports about the frequent association of t(4;11) translocation and myeloid antigen co-expression in ALL, 15,16) and significant correlation between myeloid antigen expression and TEL-AML1 fusion (resulting from the t(12;21) (p13;q22) translocation) in childhood ALL. 17,18) In our study, no specific chromosomal abnormality was observed in co-expressing acute leukemia.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Co-expression of Aberrant Antigens in Acute Leukemia

et al. 2009

View full text Add to dashboard Cite

Background: Acute leukemias co-expressing myeloid and lymphoid antigens but does not meet the criteria for biphenotypic acute leukemia (BAL) is common, however its clinical significance is not fully defined. Methods: In this study, clinical features of 68 co-expressing (myeloid and lymphoid) acute leukemias diagnosed between January 2000 and December 2006 were studied and compared with those of a control group of patients (pure AML or ALL). Results: Age, gender, initial Lactate dehydrogenase (LDH) level and cytogenetics were not different between the co-expressing group and the control group. But, the initial bone marrow blast percent was significantly higher in the co-expressing group (70% vs. 54.5%, P=0.003). Fifty five percent (16/29) of ALL and 30% (52/172) of AML patients showed myeloid and lymphoid markers concomitantly. The lymphoid antigen positive AML (Ly+ AML) patients showed significantly shorter survival rates than pure AML patients (4 year survival rate, 17.6% vs. 45.6%, P=0.002). However hematopoietic stem cell transplantation (HST) abrogated the difference (4 year survival rate, 54.7% vs. 50.6%, P=0.894). In ALL patients, survival rate was not affected by myeloid antigen co-expression (4 year survival rate 26.1% vs. 20%, P=0.954). Conclusion: Co-expression of lymphoid markers in AML should be regarded as a poor prognostic factor and more aggressive treatment such as HST should be considered.

show abstract